Eurobio Scientific: Revealed by the Covid-19
The Covid-19 crisis revealed Eurobio Scientific to investors. The small French distributor of specialized in vitro diagnostic products was one of the first companies in its industry to launch and develop PCR tests for Coronavirus in France. On February 10, the company integrated the tests from Korea's Seegene into its molecular biology range and, on March 25, Eurobio launched the marketing of its proprietary test. Six days later, the company began marketing serology tests for the Chinese SNIB to identify the presence of antibodies against the virus in patients. To date, Eurobio has received 14 million euros in new orders (nearly a quarter of its annual sales) for these products.
Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.
LPE Research is a new independent equity research firm offering research on demand to fund managers.
We believe our independent equity research on demand model dedicated to fund managers is the future, that our disruptive equity research on demand model will save money and addresses fund managers real needs, that fund managers should pay only for the equity research they need and if it creates value for them. And we ambition to become fund managers primary outperformance partner.
Our equity research services on demande services are:
- Stock conviction: independent reports
- Stock checking: on demand financial analysis
- Stock coverage: alert and coverage of specific companies
- Stock ideas (to come): list of investment opportunities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.